Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-126 |
Sentence |
denotes |
[Esmolol improves clinical outcome and tissue oxygen metabolism in patients with septic shock through controlling heart rate]. |
T2 |
127-137 |
Sentence |
denotes |
OBJECTIVE: |
T3 |
138-290 |
Sentence |
denotes |
To investigate whether esmolol could improve clinical outcome and tissue oxygen metabolism by controlling heart rate (HR) in patients with septic shock. |
T4 |
291-299 |
Sentence |
denotes |
METHODS: |
T5 |
300-373 |
Sentence |
denotes |
A single-center double-blinded randomized controlled trial was conducted. |
T6 |
374-787 |
Sentence |
denotes |
The patients suffering from septic shock received 6-hour early goal directed herapy (EGDT) with pulmonary artery wedge pressure ≥ 12 mmHg (1 mmHg = 0.133 kPa) or central venous pressure CVP) ≥ 12 mmHg requiring norepinephrine to maintain mean arterial pressure (MAP) ≥ 65 mmHg and HR ≥ 95 bpm admitted to intensive care unit (ICU) of Guangdong General Hospital from September 2013 to September 2014 were enrolled. |
T7 |
788-894 |
Sentence |
denotes |
They were randomly divided into esmolol group and control group by computer-based random number generator. |
T8 |
895-1160 |
Sentence |
denotes |
All patients received conventional basic treatment, while those in the esmolol group received in addition persistent esmolol infusion by micro pump with dosage of 0.05 mg · kg(-1) · min(-1) with the dosage adjusted to maintain HR lower than 100 bpm within 24 hours. |
T9 |
1161-1232 |
Sentence |
denotes |
The patients in control group did not receive drug intervention for HR. |
T10 |
1233-1312 |
Sentence |
denotes |
The primary end-points consisted of length of stay in ICU and 28-day mortality. |
T11 |
1313-1627 |
Sentence |
denotes |
The secondary end-points included hemodynamic parameters [HR, MAP, CVP, cardiac index (CI), stroke volume index (SVI), systemic vascular resistance index (SVRI)] and tissue oxygen metabolism parameters [central venous oxygen saturation (ScvO2), lactate level (Lac)] before and 24, 48, 72 hours after the treatment. |
T12 |
1628-1636 |
Sentence |
denotes |
RESULTS: |
T13 |
1637-1893 |
Sentence |
denotes |
A total of 48 patients with septic shock were enrolled with 24 patients in esmolol group and 24 in control group. (1) The primary end-points: compared with control group, the length of stay in the ICU in the esmolol group was significantly shortened (days: |
T14 |
1894-2208 |
Sentence |
denotes |
13.75 ± 8.68 vs. 21.70 ± 6.06, t = 3.680, P = 0.001), and 28-day mortality was significantly lowered [25.0% (6/24) vs. 62.5% (15/24 ), χ2 = 6.857, P = 0.009]. (2) The secondary end-points: there were no significant difference in the hemodynamic and tissue metabolism parameters before treatment between two groups. |
T15 |
2209-2321 |
Sentence |
denotes |
No significant difference was found between before and after treatment of all above parameters in control group. |
T16 |
2322-2482 |
Sentence |
denotes |
HR and Lac in the esmolol group were obviously declined, SVI, SVRI, SCvO2 were gradually increased, but no significant difference in MAP, CVP, and CI was found. |
T17 |
2483-2572 |
Sentence |
denotes |
Compared with the control group, HR in the esomolol group was significantly lowered (bpm: |
T18 |
2573-2701 |
Sentence |
denotes |
84.4 ± 3.5 vs. 111.2 ± 7.2, P < 0.01), SVRI and ScvO2 were significantly increased from 24 hours [SVRI (kPa · s · L(-1) ·m(-2)): |
T19 |
2702-2737 |
Sentence |
denotes |
137.9 ± 1.6 vs. 126.9 ± 1.3, ScvO2: |
T20 |
2738-2826 |
Sentence |
denotes |
0.652 ± 0.017 vs. 0.620 ± 0.017, both P < 0.01]; SVI was significantly increased (mL/m2: |
T21 |
2827-2923 |
Sentence |
denotes |
39.9 ± 2.2 vs. 36.8 ± 1.7, P < 0.01) and Lac level significantly declined from 48 hours (mmol/L: |
T22 |
2924-2959 |
Sentence |
denotes |
2.8 ± 0.3 vs. 3.4 ± 0.3, P < 0.01). |
T23 |
2960-2971 |
Sentence |
denotes |
CONCLUSION: |
T24 |
2972-3203 |
Sentence |
denotes |
The results demonstrate that HR controlled by a titrated esmolol infusion given to septic shock patients was associated with an improvement in tissue metabolism, reduction in the length of ICU stay and lowering of 28-day mortality. |
T1 |
0-126 |
Sentence |
denotes |
[Esmolol improves clinical outcome and tissue oxygen metabolism in patients with septic shock through controlling heart rate]. |
T2 |
127-137 |
Sentence |
denotes |
OBJECTIVE: |
T3 |
138-290 |
Sentence |
denotes |
To investigate whether esmolol could improve clinical outcome and tissue oxygen metabolism by controlling heart rate (HR) in patients with septic shock. |
T4 |
291-299 |
Sentence |
denotes |
METHODS: |
T5 |
300-373 |
Sentence |
denotes |
A single-center double-blinded randomized controlled trial was conducted. |
T6 |
374-787 |
Sentence |
denotes |
The patients suffering from septic shock received 6-hour early goal directed herapy (EGDT) with pulmonary artery wedge pressure ≥ 12 mmHg (1 mmHg = 0.133 kPa) or central venous pressure CVP) ≥ 12 mmHg requiring norepinephrine to maintain mean arterial pressure (MAP) ≥ 65 mmHg and HR ≥ 95 bpm admitted to intensive care unit (ICU) of Guangdong General Hospital from September 2013 to September 2014 were enrolled. |
T7 |
788-894 |
Sentence |
denotes |
They were randomly divided into esmolol group and control group by computer-based random number generator. |
T8 |
895-1160 |
Sentence |
denotes |
All patients received conventional basic treatment, while those in the esmolol group received in addition persistent esmolol infusion by micro pump with dosage of 0.05 mg · kg(-1) · min(-1) with the dosage adjusted to maintain HR lower than 100 bpm within 24 hours. |
T9 |
1161-1232 |
Sentence |
denotes |
The patients in control group did not receive drug intervention for HR. |
T10 |
1233-1312 |
Sentence |
denotes |
The primary end-points consisted of length of stay in ICU and 28-day mortality. |
T11 |
1313-1627 |
Sentence |
denotes |
The secondary end-points included hemodynamic parameters [HR, MAP, CVP, cardiac index (CI), stroke volume index (SVI), systemic vascular resistance index (SVRI)] and tissue oxygen metabolism parameters [central venous oxygen saturation (ScvO2), lactate level (Lac)] before and 24, 48, 72 hours after the treatment. |
T12 |
1628-1636 |
Sentence |
denotes |
RESULTS: |
T13 |
1637-1893 |
Sentence |
denotes |
A total of 48 patients with septic shock were enrolled with 24 patients in esmolol group and 24 in control group. (1) The primary end-points: compared with control group, the length of stay in the ICU in the esmolol group was significantly shortened (days: |
T14 |
1894-2208 |
Sentence |
denotes |
13.75 ± 8.68 vs. 21.70 ± 6.06, t = 3.680, P = 0.001), and 28-day mortality was significantly lowered [25.0% (6/24) vs. 62.5% (15/24 ), χ2 = 6.857, P = 0.009]. (2) The secondary end-points: there were no significant difference in the hemodynamic and tissue metabolism parameters before treatment between two groups. |
T15 |
2209-2321 |
Sentence |
denotes |
No significant difference was found between before and after treatment of all above parameters in control group. |
T16 |
2322-2482 |
Sentence |
denotes |
HR and Lac in the esmolol group were obviously declined, SVI, SVRI, SCvO2 were gradually increased, but no significant difference in MAP, CVP, and CI was found. |
T17 |
2483-2572 |
Sentence |
denotes |
Compared with the control group, HR in the esomolol group was significantly lowered (bpm: |
T18 |
2573-2701 |
Sentence |
denotes |
84.4 ± 3.5 vs. 111.2 ± 7.2, P < 0.01), SVRI and ScvO2 were significantly increased from 24 hours [SVRI (kPa · s · L(-1) ·m(-2)): |
T19 |
2702-2737 |
Sentence |
denotes |
137.9 ± 1.6 vs. 126.9 ± 1.3, ScvO2: |
T20 |
2738-2826 |
Sentence |
denotes |
0.652 ± 0.017 vs. 0.620 ± 0.017, both P < 0.01]; SVI was significantly increased (mL/m2: |
T21 |
2827-2923 |
Sentence |
denotes |
39.9 ± 2.2 vs. 36.8 ± 1.7, P < 0.01) and Lac level significantly declined from 48 hours (mmol/L: |
T22 |
2924-2959 |
Sentence |
denotes |
2.8 ± 0.3 vs. 3.4 ± 0.3, P < 0.01). |
T23 |
2960-2971 |
Sentence |
denotes |
CONCLUSION: |
T24 |
2972-3203 |
Sentence |
denotes |
The results demonstrate that HR controlled by a titrated esmolol infusion given to septic shock patients was associated with an improvement in tissue metabolism, reduction in the length of ICU stay and lowering of 28-day mortality. |